The aging of the central nervous system and the development of incapacitating neurological diseases like Alzheimer's disease (AD) are generally associated with a wide range of histological and pathophysiological changes eventually leading to a compromised cognitive status. Although the diverse triggers of the neurodegenerative processes and their interactions are still the topic of extensive debate, the possible contribution of cerebrovascular deficiencies has been vigorously promoted in recent years. Various forms of cerebrovascular insufficiency such as reduced blood supply to the brain or disrupted microvascular integrity in cortical regions may occupy an initiating or intermediate position in the chain of events ending with cognitive failure. When, for example, vasoconstriction takes over a dominating role in the cerebral vessels, the perfusion rate of the brain can considerably decrease causing directly or through structural vascular damage a drop in cerebral glucose utilization. Consequently, cerebral metabolism can suffer a setback leading to neuronal damage and a concomitant suboptimal cognitive capacity. The present review focuses on the microvascular aspects of neurodegenerative processes in aging and AD with special attention to cerebral blood flow, neural metabolic changes and the abnormalities in microvascular ultrastructure. In this context, a few of the specific triggers leading to the prominent cerebrovascular pathology, as well as the potential neurological outcome of the compromised cerebral microvascular system are also going to be touched upon to a certain extent, without aiming at total comprehensiveness. Finally, a set of animal models are going to be presented that are frequently used to uncover the functional relationship between cerebrovascular factors and the damage to neural networks.
Abbre6iations: Ab, beta amyloid; ACh, acetylcholine; AD, Alzheimer's disease; APP, amyloid precursor protein; BBB, blood-brain barrier; BM, basement membrane; BMT, basement membrane thickening; CA, hippocampal Ammon's horn; CAA, cerebral amyloid angiopathy; CAMCOG, Cambridge Cognitive Examination; CBF, cerebral blood flow; CGU, cerebral glucose utilization; CGRP, calcitonin gene-related peptide; ChAT, choline acetyltransferase; CMRO 2 , cerebral metabolic rate for oxygen; CNS, central nervous system; EM, electron microscopy; eNOS, endothelial NO synthase; GFAP, glial fibrillary acidic protein; GLUT-1, glucose transporter protein 1; HDS, Hasegawa's Dementia Scale; HSPG, heparan sulfate proteoglycan; mAChR, muscarinic acetylcholine receptor; MAP2, microtubule-associated protein 2; MCA, middle cerebral artery; MCAO, middle cerebral artery occlusion; MMSE, Mini Mental State Examination; NBM, nucleus basalis magnocellularis; NO, nitric oxide; NOS, nitric oxide synthase; NPY, neuropeptide-Y; PGI2, prostaglandin I2; SAH, subarachnoid hemorrhage; SHR, spontaneously hypertensive rat strain; SHR-SP, spontaneously hypertensive stroke-prone rat strain; SI, substantia innominata; SP, substance-P; PHA-L, Phaseolus vulgaris leucoagglutinin; rCBF, regional cerebral blood flow; rCGU, regional cerebral glucose utilization; SMC, smooth muscle cell; VIP, vasoactive intestinal polypeptide; WKY, Wistar-Kyoto rat strain; 2VO, bilateral carotid artery ligation, two vessel occlusion; 3VO, cerebrovascular insufficiency, three vessel occlusion.
